Samuel L. Volchenboum to Neuroblastoma
This is a "connection" page, showing publications Samuel L. Volchenboum has written about Neuroblastoma.
Connection Strength
4.047
-
Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer. 2018 12; 65(12):e27417.
Score: 0.505
-
Data Commons to Support Pediatric Cancer Research. Am Soc Clin Oncol Educ Book. 2017; 37:746-752.
Score: 0.449
-
N-linked glycan profiling in neuroblastoma cell lines. J Proteome Res. 2015 May 01; 14(5):2074-81.
Score: 0.396
-
Are molecular neuroblastoma classifiers ready for prime time? Lancet Oncol. 2009 Jul; 10(7):641-2.
Score: 0.267
-
Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer Res. 2009 May 15; 69(10):4143-9.
Score: 0.264
-
Progress in defining and treating high-risk neuroblastoma: lessons from the bench and bedside. J Clin Oncol. 2009 Mar 01; 27(7):1003-4.
Score: 0.259
-
Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group. JCO Clin Cancer Inform. 2021 12; 5:1181-1188.
Score: 0.158
-
Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open. 2021 07 01; 4(7):e2116248.
Score: 0.153
-
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021 07; 9(7).
Score: 0.153
-
Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. JCO Clin Cancer Inform. 2020 10; 4:895-905.
Score: 0.146
-
Reply to K. Beiske et al. J Clin Oncol. 2020 11 01; 38(31):3720-3721.
Score: 0.145
-
Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. J Clin Oncol. 2020 06 10; 38(17):1906-1918.
Score: 0.141
-
Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. J Natl Cancer Inst. 2017 10 01; 109(10).
Score: 0.118
-
Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017 02; 72:177-185.
Score: 0.112
-
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016 09; 65:1-10.
Score: 0.109
-
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 08; 63(8):1349-56.
Score: 0.107
-
Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study. J Clin Oncol. 2016 Mar 01; 34(7):740-6.
Score: 0.105
-
Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Sep 20; 33(27):3008-17.
Score: 0.102
-
Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer. 2015 Jan; 62(1):128-33.
Score: 0.096
-
Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. J Clin Oncol. 2014 Apr 20; 32(12):1228-35.
Score: 0.093
-
Mutations that disrupt PHOXB interaction with the neuronal calcium sensor HPCAL1 impede cellular differentiation in neuroblastoma. Oncogene. 2014 Jun 19; 33(25):3316-24.
Score: 0.088
-
Locoregional MYCN-amplified neuroblastoma. Pediatr Blood Cancer. 2012 Oct; 59(4):736-8.
Score: 0.079